Agonist-like activity of antibodies to angiotensin II receptor subtype 1 (AT1) from rats immunized with AT1 receptor peptide

• Published in: Blood pressure Vol. 8; no. 5-6; pp. 317 - 324
• Main Author: FU, MICHAEL L. X.
• Format: Journal Article
• Language: English
• Published: Stockholm Informa UK Ltd 1999; Taylor & Francis
• Subjects: agonists; Amino Acid Sequence; Angiotensin; Animals; Antibody Formation; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cell and Molecular Biology; Cell- och molekylärbiologi; Experimental diseases; Fysiologi; Gene Expression; genetics; Humans; Immunization; immunology; Kidney; Kidney - immunology; Kidney - pathology; Liver; Liver - immunology; Liver - pathology; Male; Medical sciences; Messenger; metabolism; Microbiology in the medical area; Mikrobiologi inom det medicinska området; Molecular Sequence Data; Myocardium; Myocardium - immunology; Myocardium - pathology; pathology; Physiology; Rats; Rats, Wistar; Receptor; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors; Receptors, Angiotensin - agonists; Receptors, Angiotensin - genetics; Receptors, Angiotensin - immunology; RNA; RNA, Messenger - genetics; RNA, Messenger - metabolism; Type 1; Type 2; Wistar; Hypertension; Vertebrata; Immunization; Mammalia; Rat; Antibody; Pathogenesis; Animal; Rodentia; Cardiovascular disease; Angiotensin II; Biological receptor
• ISSN: 0803-7051; 1651-1999
• DOI: 10.1080/080370599439544

In the present study, rats were immunized with angiotensin II receptor subtype 1 (AT1) receptor peptides for 3 months to see if the immunization produced specific anti-AT1 receptor antibodies and if continuous stimulation for 3 months affected blood pressure or induced morphological changes in the organs containing AT1 receptors. Our results showed that there were constant high levels of circulating antibodies throughout the study period in all rats of the immunized group, but not in the control rats, and that there were almost no significant cross-reactions of antisera with AT2 receptor peptide and alpha1 adrenoceptor peptide, except in four rats, which showed low cross-reactions with alpha1 adrenoceptor and AT2 receptor peptides. When an affinity-purified anti-AT1 receptor antibody was used, it specifically displayed the AT1-stimulatory positive chronotropic effect and also localized AT1 receptors. However, in the immunized group, saturation binding of AT1 in homogenates from kidneys showed no difference either in maximal binding sites (Bmax) or in antagonist affinity (Kd). No difference in mRNA of AT1a was found in either kidney or heart, and no morphological changes in the organs were observed, as compared with the control group. Furthermore, immunization did not cause hypertension. In conclusion, the synthetic peptide corresponding to the second extra-cellular loop of the human AT1 receptor was able to produce highly specific and functionally active anti-AT1 receptor antibodies, but unable to induce pathological structural changes or hypertension.